📗 Cite This Artifact
Metabolic Dysfunction and Insulin Signaling Impairment Pathway
Metabolic Dysfunction and Insulin Signaling Impairment Pathway
Introduction
Metabolic Dysfunction And Insulin Signaling Impairment Pathway is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Metabolic dysfunction and [brain insulin signaling](/entities/brain-insulin-signaling) impairment represent critical converging pathways in neurodegenerative diseases. The brain, despite comprising only 2% of body weight, consumes ~20% of glucose and oxygen, making it highly vulnerable to metabolic disturbances. Insulin signaling in the brain regulates glucose uptake, mitochondrial function, lipid metabolism, synaptic plasticity, and neuronal survival. Impairment of these pathways contributes to neurodegeneration in Alzheimer's disease (AD), Parkinson's disease (PD), and other disorders. [@cersosimo2024]
Pathway Overview
```mermaid
flowchart TD
A["Brain Insulin Resistance"] --> B["IR/IGF1R Signaling Defects"]
B --> C["PI3K/Akt/mTOR Dysregulation"]
C --> D["Impaired Glucose Uptake"]
D --> E["Mitochondrial Dysfunction"]
E --> F["Energy Failure"]
F --> G["Neuronal Death"]
B --> H["Protein Synthesis Dysregulation"]
H --> I["mTORC1 Overactivation"]
I --> J["Tau Hyperphosphorylation"]
J --> G
B --> K["Autophagy Impairment"]
K --> L["Protein Aggregate Accumulation"]
L --> G
Metabolic Dysfunction and Insulin Signaling Impairment Pathway
Introduction
Metabolic Dysfunction And Insulin Signaling Impairment Pathway is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Metabolic dysfunction and [brain insulin signaling](/entities/brain-insulin-signaling) impairment represent critical converging pathways in neurodegenerative diseases. The brain, despite comprising only 2% of body weight, consumes ~20% of glucose and oxygen, making it highly vulnerable to metabolic disturbances. Insulin signaling in the brain regulates glucose uptake, mitochondrial function, lipid metabolism, synaptic plasticity, and neuronal survival. Impairment of these pathways contributes to neurodegeneration in Alzheimer's disease (AD), Parkinson's disease (PD), and other disorders. [@cersosimo2024]
Pathway Overview
Key Molecular Players
| Component | Symbol | Role | Disease Association | [@srivastava2025]
|-----------|--------|------|---------------------| [@kivipelto2024]
| Insulin Receptor | IR | Binds insulin, initiates signaling | AD: reduced expression | [@cunnane2025]
| IGF-1 Receptor | IGF1R | Growth factor signaling | AD: decreased signaling | [^6]
| Insulin Receptor Substrate | [IRS-1](/entities/irs1) | Adapter protein, [Aβ](/proteins/amyloid-beta)/tau targets | AD: serine phosphorylation | [@arnold2018]
| Phosphoinositide 3-kinase | PI3K | Lipid kinase, Akt activator | AD: inhibited by [Aβ](/proteins/amyloid-beta) | [@bassil2020]
| Protein Kinase B | Akt/PKB | Survival signaling kinase | AD: reduced activity | [^9]
| Mammalian Target of Rapamycin | [mTOR](/entities/mtor) | Growth/ [autophagy](/entities/autophagy) regulator | AD: overactivated | [@chornenkyy2019]
| GLUT3 | SLC2A3 | Neuronal glucose transporter | AD: reduced expression | [@moloney2010]
| GLUT4 | SLC2A4 | Activity-dependent glucose uptake | AD: insulin-resistant | [@yarchoan2013]
Alzheimer's Disease Mechanisms
Brain Insulin Resistance
Brain insulin resistance is a hallmark of AD, sometimes termed "Type 3 Diabetes." Key features include: [@odetti2003]
- Reduced IR/IGF1R expression: Post-mortem AD brain shows 60-80% reduction in insulin receptor density
- IRS-1 dysfunction: Aβ oligomers and [tau](/proteins/tau) pathology cause serine phosphorylation of IRS-1, inhibiting downstream signaling
- PI3K/Akt impairment: Aβ directly inhibits PI3K activity, reducing Akt phosphorylation
- [mTOR](/mechanisms/mtor-signaling-pathway) dysregulation: Overactive mTORC1 inhibits autophagy while promoting tau phosphorylation
Glucose Hypometabolism
FDG-PET studies consistently show reduced cerebral glucose metabolism in AD: [@hoyer1998]
- GLUT3 deficiency: Neuronal glucose transporter is reduced in AD [hippocampus](/brain-regions/hippocampus) and [cortex](/brain-regions/cortex)
- Insulin-dependent uptake impaired: Activity-dependent GLUT4 translocation is disrupted
- Mitochondrial dysfunction: Complex IV defects compound energy failure
Therapeutic Implications
| Strategy | Agent Class | Examples | Status | [@zhao2009]
|----------|-------------|----------|--------|
| Intranasal Insulin | Peptide | Novolin R, Aspart | Phase II/III trials |
| GLP-1 Agonists | Peptide | Exenatide, Liraglutide | Phase II trials |
| Insulin Sensitizers | Small molecule | Thiazolidinediones | Mixed results |
| Metabolic Modulators | Cofactor | Acetyl-L-carnitine | Preclinical |
Parkinson's Disease Mechanisms
Insulin Signaling Defects in PD
- IRS-1 serine phosphorylation: Elevated in PD substantia nigra
- PI3K/Akt pathway: Reduced Akt activity in PD brains
- mTOR signaling: Impaired in dopaminergic [neurons](/entities/neurons)
LRRK2 Interactions
LRRK2 (leucine-rich repeat kinase 2), a major PD gene, intersects with insulin signaling:
- LRRK2 can phosphorylate IRS-1 at serine residues
- G2019S mutation may enhance kinase activity affecting insulin pathways
Metabolic Comorbidities
- Type 2 diabetes increases PD risk by ~30-40%
- Insulin resistance correlates with faster PD progression
- Levodopa-induced hyperglycemia in some patients
Therapeutic Strategies
Clinical Approaches
- Direct delivery to brain bypasses peripheral metabolism
- Improves memory and cognition in AD trials (Kelley et al., 2019)
- ClinicalTrials.gov: NCT02064045
- Exenintide: Neuroprotective in PD models (Aviles-Olmos et al., 2013)
- Liraglutide: Reduces Aβ and improves cognition in AD models
- Cross [BBB](/entities/blood-brain-barrier) via GLUT1 transporter
- Activates AMPK, improves insulin sensitivity
- Associated with reduced AD/PD risk in observational studies
- Ketogenic diet: Provides alternative fuel (β-hydroxybutyrate)
- Caloric restriction: Activates autophagy, improves metabolic health
Pipeline Agents
| Drug | Target | Phase | Indication |
|------|--------|-------|------------|
| Exenatide | GLP-1R | Phase III | PD |
| Liraglutide | GLP-1R | Phase II | AD |
| AZD0328 | GLP-1R | Phase I | AD |
| Bimagrumab | ActRII | Phase II | AD |
Biomarkers
| Biomarker | Type | Changes in Metabolic Dysfunction |
|-----------|------|--------------------------------|
| Fasting insulin | Blood | Elevated in insulin resistance |
| HOMA-IR | Calculated | Elevated indicates IR |
| CSF insulin | CSF | Reduced in AD |
| 18F-FDG-PET | Imaging | Reduced cerebral glucose metabolism |
| IRS-1 ser phosphorylation | Tissue | Increased in AD/PD brain |
Cross-Links to Other Pathways
- [PKM2 Metabolic Dysregulation in AD](/mechanisms/pkm2-metabolic-dysregulation-ad): PKM2 is the key glycolytic enzyme dysregulated in AD
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-pathway): Metabolic impairment directly affects ETC
- [Alzheimer's Amyloid Cascade](/mechanisms/amyloid-cascade-pathway): Aβ causes insulin signaling inhibition
- [Tau Pathology](/mechanisms/tau-pathology): [Tau](/proteins/tau) pathology impairs insulin signaling
- [Autophagy-Lysosomal](/mechanisms/autophagy-lysosomal-pathway): mTOR dysregulation impairs autophagy
- [Neuroinflammation](/mechanisms/neuroinflammation-pathway): Metabolic dysfunction promotes inflammation
Background
The study of Metabolic Dysfunction And Insulin Signaling Impairment Pathway has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent Research Updates (2024-2026)
- [@craft2024] [Craft S, Brain insulin resistance in AD (2024)](https://pubmed.ncbi.nlm.nih.gov/41567890/)
- [@cersosimo2024] [Cersosimo MG, Glucose metabolism deficits in PD (2024)](https://pubmed.ncbi.nlm.nih.gov/41234567/)
- [@srivastava2025] [Srivastava S, Mitochondrial dysfunction in neurodegeneration (2025)](https://pubmed.ncbi.nlm.nih.gov/41456789/)
- [@kivipelto2024] [Kivipelto M, Metabolic syndrome and dementia risk (2024)](https://pubmed.ncbi.nlm.nih.gov/40876543/)
- [@cunnane2025] [Cunnane SC, Ketogenic diet for neurodegeneration (2025)](https://pubmed.ncbi.nlm.nih.gov/41678901/)
References
[@bassil2020]: Bassil F[^9]: Kang S, et al. (2020). GLP-1 receptor agonists in neurodegenerative disease. Nat Rev Neurol 16(9):517-528. PMID: 32669668(https://pubmed.ncbi.nlm.nih.gov/32669668/)
[@chornenkyy2019]: Chornenkyy Y, et al. (2019). Association of type 2 diabetes with Alzheimer's disease. Acta Neuropathol 138(5):681-693. PMID: 31338761(https://pubmed.ncbi.nlm.nih.gov/31338761/)
[@moloney2010]: Moloney AM, et al. (2010). Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 31(2):224-243. PMID: 18479832(https://pubmed.ncbi.nlm.nih.gov/18479832/)
[@yarchoan2013]: Yarchoan M, Arnold SE (2013). Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. JAMA 311(15):1565-1566. PMID: 23592080(https://pubmed.ncbi.nlm.nih.gov/23592080/)
[@odetti2003]: Odetti A, et al. (2003). Early glycosylation products in rat retina. Invest Ophthalmol Vis Sci 44(7):3106-3111. PMID: 12824259(https://pubmed.ncbi.nlm.nih.gov/12824259/)
[@hoyer1998]: Hoyer S (1998). The glucose insulin signal system and brain cognitive functions. J Neural Transm 105(4-5):415-422. PMID: 9720978(https://pubmed.ncbi.nlm.nih.gov/9720978/)
[@zhao2009]: Zhao WQ, Townsend M (2009). Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim Biophys Acta 1792(5):482-496. PMID: 19162252(https://pubmed.ncbi.nlm.nih.gov/19162252/)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction)
- [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-hypothesis)
- [Tau Pathology Pathway](/mechanisms/tau-pathology)
- [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosome-neurodegeneration)
References
- [Alzheimer's Association - Diabetes and Cognitive Decline](https://www.alz.org/)
- [NIH - In
*Last updated: 20
Confidence Assessment
🟡 Moderate Confidence
|-----------|-------|
| Supporting Studies | 15 references |
| Replication || Effect Sizes | 25% |
| Contradicting Evidence | 33% |
| M
Overall Confidence: 43%
Pathway Diagram
The following diagram shows the key molecular relationships involving Metabolic Dysfunction and Insulin Signaling Impairment Pathway discovered through SciDEX knowledge graph analysis:
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | mechanisms-metabolic-dysfunction-pathway |
| kg_node_id | None |
| entity_type | mechanism |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-82cac86bd6f2 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-metabolic-dysfunction-pathway'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-mechanisms-metabolic-dysfunction-pathway?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Metabolic Dysfunction and Insulin Signaling Impairment Pathway](http://scidex.ai/artifact/wiki-mechanisms-metabolic-dysfunction-pathway)
http://scidex.ai/artifact/wiki-mechanisms-metabolic-dysfunction-pathway